Top

Published in:

Open Access 01-03-2021 | Probiotics | Original Research

The Effect of Probiotics Supplementation on Gut Microbiota After Helicobacter pylori Eradication: A Multicenter Randomized Controlled Trial

Authors: Bo Tang, Li Tang, Cheng Huang, Chuan Tian, Ling Chen, Zhijun He, Guodong Yang, Luo Zuo, Guoce Zhao, En Liu, Sumin Wang, Hui Lin, Jialin He, Shiming Yang

Published in: Infectious Diseases and Therapy | Issue 1/2021

Abstract

Introduction

Helicobacter pylori eradication therapy may lead to the perturbation of gut microbiota. We aim to investigate the impact of probiotics on eradication rate and gut microbiota during eradication therapy.

Methods

A total of 162 patients receiving bismuth quadruple therapy were enrolled and randomly assigned to groups given probiotics (n = 83) or placebo (n = 79) for 4 weeks. Fecal samples were collected before treatment and 2, 4, 6, and 8 weeks after eradication therapy. Gut microbiota was analyzed by 16S rRNA high-throughput sequencing.

Results

The eradication rates in the placebo and probiotics group were 82.43% and 87.01%, respectively (P > 0.05). Compared with baseline, alpha and beta diversity was significantly altered 2 weeks after eradication in both groups, which was restored at week 8. There were no significant differences in diversity between the two groups. H. pylori eradication therapy resulted in enrichment of some detrimental bacteria taxa such as Shigella, Klebsiella, and Streptococcus, while probiotics supplementation could rapidly restore these taxa levels after eradication and increase the taxa of Bacillus and Lactobacillales. Functional analysis revealed that lipopolysaccharide biosynthesis and polymyxin resistance pathways were significantly enriched after eradication, while probiotics supplementation mainly enriched the cofactors and vitamins metabolism pathways. Increased relative abundances of Roseburia and Dialister were associated with the positive eradication outcome.

Conclusions

Probiotics supplementation might help to construct a beneficial profile of gut microbiota after eradication therapy. Specific bacteria taxa are associated with H. pylori eradication outcome. These findings may be of value in rational use of probiotics during H. pylori eradication.

Trial Registration

Chinese Clinical Trial Registry, ChiCTR1900022116.

Available only for authorised users

Leja M, Grinberga-Derica I, Bilgilier C, Steininger C. Review: epidemiology of Helicobacter pylori infection. Helicobacter. 2019;24(Suppl 1):e12635. https://doi.org/10.1111/hel.12635.CrossRefPubMed

Waskito LA, Salama NR, Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2018;23(Suppl 1):e12516. https://doi.org/10.1111/hel.12516.CrossRefPubMed

Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288.CrossRefPubMed

Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085–95. https://doi.org/10.1056/NEJMoa1708423.CrossRefPubMed

O’Connor A, Liou JM, Gisbert JP, O’Morain C. Review: treatment of Helicobacter pylori infection 2019. Helicobacter. 2019;24(Suppl 1):e12640. https://doi.org/10.1111/hel.12640.CrossRefPubMed

Liu WZ, Xie Y, Lu H, et al. Fifth Chinese national consensus report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2):e12475. https://doi.org/10.1111/hel.12475.CrossRefPubMed

Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352(6285):544–5. https://doi.org/10.1126/science.aad9358.CrossRefPubMedPubMedCentral

Hsu PI, Pan CY, Kao JY, et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018;23(4):e12498. https://doi.org/10.1111/hel.12498.CrossRefPubMed

Trifan A, Girleanu I, Cojocariu C, et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J Gastroenterol. 2013;19(42):7476–9. https://doi.org/10.3748/wjg.v19.i42.7476.CrossRefPubMedPubMedCentral

10.

Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014;124(10):4212–8. https://doi.org/10.1172/JCI72333.CrossRefPubMedPubMedCentral

11.

Oh B, Kim BS, Kim JW, et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: randomized controlled trial. Helicobacter. 2016;21(3):165–74. https://doi.org/10.1111/hel.12270.CrossRefPubMed

12.

Liou JM, Chen CC, Chang CM, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19(10):1109–20. https://doi.org/10.1016/S1473-3099(19)30272-5.CrossRefPubMed

13.

Chen L, Xu W, Lee A, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine. 2018;35:87–96. https://doi.org/10.1016/j.ebiom.2018.08.028.CrossRefPubMedPubMedCentral

14.

McNicholl AG, Molina-Infante J, Lucendo AJ, et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529. https://doi.org/10.1111/hel.12529.CrossRefPubMed

15.

Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. https://doi.org/10.1097/MD.0000000000015180.CrossRef

16.

Gotoda T, Takano C, Kusano C, et al. Gut microbiome can be restored without adverse events after Helicobacter pylori eradication therapy in teenagers. Helicobacter. 2018;23(6):e12541. https://doi.org/10.1111/hel.12541.CrossRefPubMed

17.

Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. https://doi.org/10.1038/nature08821.CrossRefPubMedPubMedCentral

18.

Hsu PI, Pan CY, Kao JY, et al. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. J Gastroenterol Hepatol. 2019;34(11):1968–76. https://doi.org/10.1111/jgh.14736.CrossRefPubMed

19.

Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 2020;11(3):569–80. https://doi.org/10.1080/19490976.2019.1681861.CrossRefPubMed

20.

Bartley A, Yang T, Arocha R, et al. Increased abundance of Lactobacillales in the colon of beta-adrenergic receptor knock out mouse is associated with increased gut bacterial production of short chain fatty acids and reduced IL17 expression in circulating CD4+ immune cells. Front Physiol. 2018;9:1593. https://doi.org/10.3389/fphys.2018.01593.CrossRefPubMedPubMedCentral

21.

Jiao N, Baker SS, Nugent CA, et al. Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis. Physiol Genomics. 2018;50(4):244–54. https://doi.org/10.1152/physiolgenomics.00114.2017.CrossRefPubMed

22.

Del Chierico F, Abbatini F, Russo A, et al. Gut microbiota markers in obese adolescent and adult patients: age-dependent differential patterns. Front Microbiol. 2018;9:1210. https://doi.org/10.3389/fmicb.2018.01210.CrossRefPubMedPubMedCentral

23.

Ze X, Duncan SH, Louis P, Flint HJ. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 2012;6(8):1535–43. https://doi.org/10.1038/ismej.2012.4.CrossRefPubMedPubMedCentral

24.

Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–73. https://doi.org/10.1126/science.1241165.CrossRefPubMed

25.

Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23(6):716–24. https://doi.org/10.1016/j.chom.2018.05.003.CrossRefPubMed

26.

Parks BW, Nam E, Org E, et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 2013;17(1):141–52. https://doi.org/10.1016/j.cmet.2012.12.007.CrossRefPubMedPubMedCentral

27.

Lee J, Choi J, Selen Alpergin ES, et al. Loss of hepatic mitochondrial long-chain fatty acid oxidation confers resistance to diet-induced obesity and glucose intolerance. Cell Rep. 2017;20(3):655–67. https://doi.org/10.1016/j.celrep.2017.06.080.CrossRefPubMedPubMedCentral

28.

Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between H. pylori infection and insulin resistance: a systematic review. Helicobacter. 2011;16(2):79–88. https://doi.org/10.1111/j.1523-5378.2011.00822.x.

29.

Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220–30.CrossRefPubMedPubMedCentral

30.

Myllyluoma E, Ahlroos T, Veijola L, Rautelin H, Tynkkynen S, Korpela R. Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. Int J Antimicrob Agents. 2007;29(1):66–72. https://doi.org/10.1016/j.ijantimicag.2006.08.034.CrossRefPubMed

31.

Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol. 2009;58(Pt 5):663–70. https://doi.org/10.1099/jmm.0.47615-0.CrossRefPubMed

32.

Pacifico L, Osborn JF, Bonci E, Romaggioli S, Baldini R, Chiesa C. Probiotics for the treatment of Helicobacter pylori infection in children. World J Gastroenterol. 2014;20(3):673–83. https://doi.org/10.3748/wjg.v20.i3.673.CrossRefPubMedPubMedCentral

33.

Wang ZJ, Chen XF, Zhang ZX, et al. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathog. 2017;109:156–61. https://doi.org/10.1016/j.micpath.2017.05.035.CrossRefPubMed

34.

Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001;15(2):163–9. https://doi.org/10.1046/j.1365-2036.2001.00923.x.CrossRefPubMed

35.

Luyer MD, Buurman WA, Hadfoune M, et al. Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun. 2005;73(6):3686–92. https://doi.org/10.1128/IAI.73.6.3686-3692.2005.CrossRefPubMedPubMedCentral

Title: The Effect of Probiotics Supplementation on Gut Microbiota After Helicobacter pylori Eradication: A Multicenter Randomized Controlled Trial
Authors: Bo Tang
Li Tang
Cheng Huang
Chuan Tian
Ling Chen
Zhijun He
Guodong Yang
Luo Zuo
Guoce Zhao
En Liu
Sumin Wang
Hui Lin
Jialin He
Shiming Yang
Publication date: 01-03-2021
Publisher: Springer Healthcare
Keywords: Probiotics
Helicobacter Pylori
Respiratory Microbiota
Published in: Infectious Diseases and Therapy / Issue 1/2021
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-020-00372-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Trial Registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study

Lost to Follow-up and Predictors Among HIV-Exposed Infants in Northwest Ethiopia

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study

Epidemiology, Susceptibility, and Risk Factors Associated with Mortality in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Abdominal Solid Organ Transplant Recipients: A Retrospective Cohort Study

Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review

The Seasonality of Peripheral Venous Catheter-Related Bloodstream Infections

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials